Releases New Report on the Hemato Oncology Testing Market 2020-2025 | Top Key Players - Roche, Abbott, Thermo Fisher, QIAGEN NV, Bio-Rad Lab, Illumina, MolecularMD, Invivoscribe

Global Hemato Oncology Testing Market Synopsis:

The report covers a forecast and an analysis of the Hemato Oncology Testing Market on a global and regional level. The study provides historical data for 2015, 2016, 2017 and 2018 along with a forecast from 2020 to 2025 based on revenue (USD Million) and volume (Kilotons). The study includes drivers and restraints of the Hemato Oncology Testing Market along with the impact they have on the demand over the forecast period.

Some of the most significant key factors driving the growth of the Global Hemato Oncology Testing Market are rapid growth in the global prevalence of hematologic cancer, increasing awareness regarding personalized medicines, and growing collaborations for developing new assays.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/273344 .

In terms of the geographic analysis, North America dominated the market in 2018; APAC is expected to register the highest CAGR in the market during the forecast period. Growth in the APAC market is driven mainly by the large patient population, and increasing focus of major players on expanding in this region will drive market growth.

This report contains a complete product overview and its scope in the market to define the key terms and provide the clients a holistic idea of the market and its tendency. It comprehensively evaluates the Global Hemato Oncology Testing Market with different perspectives for the purpose of providing a detailed, informative, and accurate analysis of regional growth, competition, market segmentation, and other important aspects.

Global Key Players:

1 Roche

2 Abbott Laboratories

3 Thermo Fisher Scientific

4 QIAGEN N.V.

5 Bio-Rad Laboratories

6 Illumina

7 MolecularMD

8 Invivoscribe

9 Asuragen

10 Adaptive Biotechnologies

11 ArcherDx

12 ARUP Laboratories and More………………

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Hemato Oncology Testing Market Report 2020” @ https://www.businessindustryreports.com/buy-now/273344/single .

Product Type Segmentation

1 Leukemia Testing

2 Acute Myeloid Testing

3 Multiple Myeloma Testing

Industry Segmentation

1 Clinical Laboratories

2 Hospitals

Latest Medical Industry News:

Roche (July 13, 2020) - Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer - Roche today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq (atezolizumab) to Avastin (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.

“Ovarian cancer remains one of the most aggressive cancers and is difficult to treat in its advanced stages,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “While we are disappointed by these results, we remain committed to improving outcomes for women living with this disease and are pleased that Avastin remains a key component in the treatment of front-line ovarian cancer.”

Data for the overall survival (OS) co-primary endpoint are currently immature and follow-up will continue until the next planned analysis. Results from IMagyn050 will be further evaluated in order to inform the Tecentriq gynaecologic development programme. The Tecentriq programme in ovarian cancer and cervical cancers builds on the combination with Avastin, which has helped women with newly diagnosed, advanced or relapsed ovarian and cervical cancers live without their disease getting worse, as demonstrated in results across seven pivotal Phase III trials that involved more than 5,000 women.

Roche has an extensive development programme for Tecentriq, including multiple ongoing and planned Phase III studies across lung, genitourinary, skin, breast, gastrointestinal, gynaecological, and head and neck cancers. This includes studies evaluating Tecentriq both alone and in combination with other medicines.

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/273344 .

Major Points in Table of Contents:

Global Hemato Oncology Testing Market Report 2020

1 Hemato Oncology Testing Product Definition

2 Global Hemato Oncology Testing Market Manufacturer Share and Market Overview

2.1 Global Manufacturer Hemato Oncology Testing Shipments

2.2 Global Manufacturer Hemato Oncology Testing Business Revenue

2.3 Global Hemato Oncology Testing Market Overview

2.4 COVID-19 Impact on Hemato Oncology Testing Industry

3 Manufacturer Hemato Oncology Testing Business Introduction

3.1 F. Hoffmann-La Roche Hemato Oncology Testing Business Introduction

3.2 Abbott Laboratories Hemato Oncology Testing Business Introduction

3.3 Thermo Fisher Scientific Hemato Oncology Testing Business Introduction

3.4 QIAGEN N.V. Hemato Oncology Testing Business Introduction

3.5 Bio-Rad Laboratories Hemato Oncology Testing Business Introduction

3.6 Illumina Hemato Oncology Testing Business Introduction

About us

BusinessindustryReports.com is a digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic, and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.